Patents by Inventor Eric Valeur

Eric Valeur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
    Publication number: 20210346509
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: April 15, 2021
    Publication date: November 11, 2021
    Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
  • GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20200268898
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: November 7, 2018
    Publication date: August 27, 2020
    Inventors: Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
  • Therapeutic agents
    Patent number: 10414726
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: September 17, 2019
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
    Publication number: 20190134214
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury III
  • THERAPEUTIC AGENTS
    Publication number: 20180118684
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Application
    Filed: September 26, 2017
    Publication date: May 3, 2018
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas GOLDING, Christiane RIEDINGER, Roger John GRIFFIN, Ian Robert HARDCASTLE, Eric VALEUR, Anna Frances WATSON, Martin NOBLE
  • THERAPEUTIC AGENTS
    Publication number: 20160355478
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Application
    Filed: May 10, 2016
    Publication date: December 8, 2016
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas GOLDING, Christiane RIEDINGER, Roger John GRIFFIN, Ian Robert HARDCASTLE, Eric VALEUR, Anna Frances WATSON, Martin NOBLE
  • Complement pathway modulators and uses thereof
    Patent number: 9452990
    Abstract: The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: September 27, 2016
    Assignee: NOVARTIS AG
    Inventors: Michael Dechantsreiter, Jonathan E. Grob, Aengus Macsweeney, Wolfgang Miltz, Stefan Andreas Randl, Richard Sedrani, Holger Sellner, Finton Sirockin, Eric Valeur
  • Therapeutic agents
    Patent number: 9358222
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 7, 2016
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones
    Patent number: 9233937
    Abstract: Arylpyrazinone derivatives of formula (I), as insulin secretion stimulators, the preparation and use of these pyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: January 12, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Gerard Botton, Eric Valeur, Christine Charon, Micheline Kergoat, Samer Elbawab
  • Complement Pathway Modulators and Uses Thereof
    Publication number: 20150126492
    Abstract: The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 7, 2015
    Applicant: NOVARTIS AG
    Inventors: Michael Dechantsreiter, Jonathan E. Grob, Aengus Macsweeney, Wolfgang Miltz, Stefan Andreas Randl, Richard Sedrani, Holger Sellner, Finton Sirockin, Eric Valeur
  • ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE
    Publication number: 20140329837
    Abstract: Arylpyrazinone derivatives of formula (I), as insulin secretion stimulators, the preparation and use of these pyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Application
    Filed: July 22, 2014
    Publication date: November 6, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Gerard BOTTON, Eric VALEUR, Christine CHARON, Micheline KERGOAT, Samer ELBAWAB
  • Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
    Patent number: 8835634
    Abstract: The present invention relates to methods for the treatment of a pathology associated with hyperglycaemia, particularly diabetes, by administering quinoxalinone compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in the claims. The compounds have activity as insulin secretion stimulators. The invention also relates to the preparation and use of these quinoxalinone compounds for modulating insulin secretion in insulin-1 cells by contacting the cells with the compounds.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: September 16, 2014
    Assignee: Merck Patent GmbH
    Inventors: Gerard Botton, Eric Valeur, Micheline Kergoat, Christine Charon, Samer Elbawab
  • Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof
    Patent number: 8815859
    Abstract: Arylpyrazinone derivatives of formula (I), as insulin secretion stimulators, the preparation and use of these pyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: August 26, 2014
    Assignee: Merck Patent GmbH
    Inventors: Gérard Botton, Eric Valeur, Christine Charon, Micheline Kergoat, Samer Elbawab
  • THERAPEUTIC AGENTS
    Publication number: 20140194486
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Application
    Filed: November 20, 2013
    Publication date: July 10, 2014
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas GOLDING, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
    Patent number: 8642617
    Abstract: The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: February 4, 2014
    Assignee: Merck Patent GmbH
    Inventors: Gérard Botton, Eric Valeur, Micheline Kergoat, Christine Charon, Samer Elbawab
  • Therapeutic agents
    Patent number: 8618158
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: December 31, 2013
    Assignee: Cancer Research Technology Limited
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
    Patent number: 8609689
    Abstract: The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 17, 2013
    Assignee: Merck Patent GmbH
    Inventors: Gerard Botton, Eric Valeur, Micheline Kergoat, Christine Charon, Samer Elbawab
  • Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
    Patent number: 8486964
    Abstract: The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: July 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Eric Valeur, Franck Lepifre, Didier Roche, Denis Carniato, Serge Christmann-Franck, Fabien Schmidlin
  • Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
    Patent number: 8415352
    Abstract: The present invention relates to quinoxalinone derivatives of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein, as insulin secretion stimulators. Specific such quinoxaline compounds are also an aspect of the invention. The invention also relates to the preparation and use of these quinoxalinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: April 9, 2013
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Gérard Botton, Eric Valeur, Micheline Kergoat, Christine Charon, Samer Elbawab
  • PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES
    Publication number: 20130023537
    Abstract: The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 24, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Gérard BOTTON, Eric VALEUR, Micheline KERGOAT, Christine CHARON, Samer ELBAWAB